IPSEN (OTCMKTS:IPSEY) Share Price Passes Above 200-Day Moving Average – What’s Next?

IPSEN (OTCMKTS:IPSEY)’s stock price passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $33.02 and traded as high as $35.55. IPSEN shares last traded at $35.55, with a volume of 288 shares trading hands.

Wall Street Analyst Weigh In

IPSEY has been the subject of several analyst reports. BNP Paribas cut IPSEN to an “underperform” rating in a research note on Wednesday, November 26th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of IPSEN in a research note on Monday, November 3rd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold”.

IPSEN Stock Performance

The firm has a 50 day moving average of $35.41 and a two-hundred day moving average of $33.09.

About IPSEN

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.